hydrochlorothiazide has been researched along with Proteinuria in 53 studies
Hydrochlorothiazide: A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. It is used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism.
hydrochlorothiazide : A benzothiadiazine that is 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide substituted by a chloro group at position 6 and a sulfonamide at 7. It is diuretic used for the treatment of hypertension and congestive heart failure.
Proteinuria: The presence of proteins in the urine, an indicator of KIDNEY DISEASES.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The aim of the study was to evaluate the effect of spironolactone versus spironolactone plus hydrochlorothiazide in decreasing proteinuria in type 2 diabetic mellitus (T2DM) patients." | 9.20 | Evaluation of spironolactone plus hydrochlorothiazide in reducing proteinuria in type 2 diabetic nephropathy. ( Behradmanesh, MS; Karami Horestani, M; Kheiri, S; Momeni, A, 2015) |
| " In this study, we assessed the additive effects of hydrochlorothiazide (HCTZ) on reducing proteinuria in CKD patients under treatment with losartan (LS)." | 9.19 | Impact of combined losartan/hydrochlorothiazide on proteinuria in patients with chronic kidney disease and hypertension. ( Fujisaki, K; Higashi, H; Hirakata, H; Kanai, H; Katafuchi, R; Kitazono, T; Nakano, T; Nakayama, M; Taniguchi, M; Tsuruya, K, 2014) |
| "We sought to compare the effect of manidipine versus hydrochlorothiazide (HCTZ) in addition to candesartan on the urinary albumin excretion rate (UAER) in hypertensive patients with type II diabetes and microalbuminuria." | 9.12 | Addition of manidipine improves the antiproteinuric effect of candesartan in hypertensive patients with type II diabetes and microalbuminuria. ( Corradi, L; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Rinaldi, A; Zoppi, A, 2007) |
| "Enalapril and enalapril/hydrochlorothiazide are effective in treating mild to moderate essential hypertension, and efficacy has been demonstrated for up to 48 weeks." | 9.05 | A controlled multiclinic study to compare the antihypertensive effects of MK-421, hydrochlorothiazide, and MK-421 combined with hydrochlorothiazide in patients with mild to moderate essential hypertension. ( Vidt, DG, 1984) |
| "We randomized 495 men with uncomplicated hypertension (diastolic BP, 92 to 109 mm Hg) to one of five captopril regimens at the following dosages: 12." | 9.05 | Low-dose captopril for the treatment of mild to moderate hypertension. I. Results of a 14-week trial. Veterans Administration Cooperative Study Group on Antihypertensive Agents. ( , 1984) |
| "BEAHIT (Benidipine and Hydrochlorothiazide in Fosinopril Treated Chronic Kidney Disease Patients with Hypertension) was approved by Changzheng Hospital Ethics Committee (CZ-20160504-16)." | 5.24 | Comparison of efficacy and safety between benidipine and hydrochlorothiazide in fosinopril-treated hypertensive patients with chronic kidney disease: protocol for a randomised controlled trial. ( Dai, B; Lv, J; Mei, C; Wang, Y; Xue, C; Yang, B; Yu, S; Zhao, G; Zhou, C, 2017) |
| " The aim of the study was to evaluate the effect of spironolactone versus spironolactone plus hydrochlorothiazide in decreasing proteinuria in type 2 diabetic mellitus (T2DM) patients." | 5.20 | Evaluation of spironolactone plus hydrochlorothiazide in reducing proteinuria in type 2 diabetic nephropathy. ( Behradmanesh, MS; Karami Horestani, M; Kheiri, S; Momeni, A, 2015) |
| " In this study, we assessed the additive effects of hydrochlorothiazide (HCTZ) on reducing proteinuria in CKD patients under treatment with losartan (LS)." | 5.19 | Impact of combined losartan/hydrochlorothiazide on proteinuria in patients with chronic kidney disease and hypertension. ( Fujisaki, K; Higashi, H; Hirakata, H; Kanai, H; Katafuchi, R; Kitazono, T; Nakano, T; Nakayama, M; Taniguchi, M; Tsuruya, K, 2014) |
| "0] g/24 h proteinuria) were treated during 6-week periods with placebo, ARB (100 mg/d losartan), and ARB plus diuretics (100 mg/d losartan plus 25 mg/d hydrochlorothiazide) combined with consecutively regular and low sodium diets (193 ± 62 versus 93 ± 52 mmol Na(+)/d)." | 5.15 | Effects of antiproteinuric intervention on elevated connective tissue growth factor (CTGF/CCN-2) plasma and urine levels in nondiabetic nephropathy. ( Goldschmeding, R; Hemmelder, MH; Laverman, GD; Navis, G; Nguyen, TQ; Slagman, MC; Vogt, L; Waanders, F, 2011) |
| "Urinary KIM-1 level was increased in patients with nondiabetic CKD with proteinuria and decreased in parallel with proteinuria by using losartan, sodium restriction, their combination, losartan plus HCT, and the latter plus sodium restriction." | 5.14 | Effect of renin-angiotensin-aldosterone system inhibition, dietary sodium restriction, and/or diuretics on urinary kidney injury molecule 1 excretion in nondiabetic proteinuric kidney disease: a post hoc analysis of a randomized controlled trial. ( Bonventre, JV; Damman, K; Hamming, I; Leuvenink, H; Navis, G; Vaidya, VS; van Goor, H; Vogt, L; Waanders, F, 2009) |
| "We sought to compare the effect of manidipine versus hydrochlorothiazide (HCTZ) in addition to candesartan on the urinary albumin excretion rate (UAER) in hypertensive patients with type II diabetes and microalbuminuria." | 5.12 | Addition of manidipine improves the antiproteinuric effect of candesartan in hypertensive patients with type II diabetes and microalbuminuria. ( Corradi, L; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Rinaldi, A; Zoppi, A, 2007) |
| "In older patients with isolated systolic hypertension, antihypertensive treatment starting with the dihydropyridine calcium-channel blocker, nitrendipine, did not decrease blood pressure at the expense of renal function and prevented the development of proteinuria, especially in diabetic patients." | 5.09 | Follow-up of renal function in treated and untreated older patients with isolated systolic hypertension. Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. ( Birkenhäger, WH; de Leeuw, PW; Efstratopoulos, AD; Fagard, R; Leonetti, G; Nachev, C; Rodicio, JL; Staessen, JA; Thijs, L; Tuomilehto, J; Voyaki, SM; Wang, JG, 2001) |
| "Enalapril and enalapril/hydrochlorothiazide are effective in treating mild to moderate essential hypertension, and efficacy has been demonstrated for up to 48 weeks." | 5.05 | A controlled multiclinic study to compare the antihypertensive effects of MK-421, hydrochlorothiazide, and MK-421 combined with hydrochlorothiazide in patients with mild to moderate essential hypertension. ( Vidt, DG, 1984) |
| "We randomized 495 men with uncomplicated hypertension (diastolic BP, 92 to 109 mm Hg) to one of five captopril regimens at the following dosages: 12." | 5.05 | Low-dose captopril for the treatment of mild to moderate hypertension. I. Results of a 14-week trial. Veterans Administration Cooperative Study Group on Antihypertensive Agents. ( , 1984) |
| " 1D11, diltiazem, and hydrochlorothiazide (HCT) attenuated the development of hypertension, proteinuria, and glomerular injury." | 3.78 | Renoprotective effects of anti-TGF-β antibody and antihypertensive therapies in Dahl S rats. ( Chen, CC; Dahly-Vernon, AJ; Dunn, KM; Ledbetter, SR; Murphy, SR; Roman, RJ; Williams, JM, 2012) |
| "Thiazide doses equivalent to 1 to 2 mg/kg/d of hydrochlorothiazide (HCTZ) have been proposed to correct hypercalciuria and prevent kidney failure in patients with Dent disease." | 3.74 | Effect of hydrochlorothiazide on urinary calcium excretion in dent disease: an uncontrolled trial. ( Azizi, M; Baudouin, V; Blanchard, A; Boudailliez, B; Charbit, M; Deschesnes, G; Ezzhair, N; Loirat, C; Macher, MA; Mogenet, A; Niaudet, P; Peyrard, S; Vargas-Poussou, R, 2008) |
| "Hydrochlorothiazide (HCTZ) is used to manage hypertension and heart failure; however, its side effects include mild hypokalemia, metabolic abnormalities, and volume depletion, which might have deleterious effects on renal and endothelial function." | 3.74 | Thiazide-induced subtle renal injury not observed in states of equivalent hypokalemia. ( Byer, K; Croker, BP; Hu, H; Johnson, RJ; Mu, W; Nakagawa, T; Patel, JM; Reungjui, S; Roncal, CA; Simoni, J; Sitprija, V; Srinivas, T; Wesson, D, 2007) |
| "Addition of hydrochlorothiazide can overcome the blunting of the therapeutic efficacy of ACE inhibition on proteinuria and blood pressure by a high sodium intake." | 3.70 | The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide. ( Buter, H; de Jong, PE; de Zeeuw, D; Hemmelder, MH; Navis, G, 1998) |
| " The aim of this study was to compare the effects of an equivalent reduction in blood pressure produced by the angiotensin-converting enzyme (ACE) inhibitor spirapril (SPI) and an antihypertensive triple drug combination of hydralazine, reserpine and hydrochlorothiazide (HRH) on kidney function, proteinuria and renal structure in hypertensive diabetic rats." | 3.70 | Control of glomerular hyperfiltration and renal hypertrophy by an angiotensin converting enzyme inhibitor prevents the progression of renal damage in hypertensive diabetic rats. ( Armini, L; Bardelli, M; Calci, M; Campanacci, L; Candido, R; Carretta, R; Fabris, B; Fazio, M; Fischetti, F, 1999) |
| "Patients with high blood pressure are often overweight or even obese." | 2.71 | [Arterial hypertension in obese patients. Rationale for a prospective medical care study in the family doctor's practice]. ( Bramlage, P; Kirch, W; Sharma, AM, 2004) |
| "Renal hemodynamics, albuminuria and metabolic parameters were evaluated for a period of one year." | 2.67 | Treatment of arterial hypertension in diabetic humans: importance of therapeutic selection. ( Bakris, GL; Barnhill, BW; Sadler, R, 1992) |
| "Hypertension was induced in uninephrectomized control rats (UNx) by subcutaneous implantation of a DOCA pellet plus administration of 1% NaCl in the drinking water (DOCA-salt) for 3 wk." | 1.43 | Pentosan polysulfate preserves renal microvascular P2X1 receptor reactivity and autoregulatory behavior in DOCA-salt hypertensive rats. ( Cha, H; Cook, AK; Guan, Z; Inscho, EW; Pollock, DM; Pollock, JS; Singletary, ST; Van Beusecum, JP, 2016) |
| "Type 2 diabetic kidney disease (DKD) is frequently accompanied by uncontrollable hypertension due to the sodium sensitivity inherent in DKD and to diuretic-resistant edema." | 1.42 | Renoprotective effects of thiazides combined with loop diuretics in patients with type 2 diabetic kidney disease. ( Hirai, K; Hoshino, T; Ito, K; Kaku, Y; Miyazawa, H; Mori, H; Ookawara, S; Tabei, K; Ueda, Y; Yoshida, I, 2015) |
| "We describe a patient with diabetic nephropathy and proteinuria who developed a remarkable hyperkalaemia on treatment with an angiotensin-receptor blocker." | 1.34 | Treating proteinuria in a diabetic patient despite hyperkalaemia due to hyporeninaemic hypoaldosteronism. ( Bolk, JH; Ijpelaar, DH; van Nieuwkoop, C, 2007) |
| "5 mg/kg/day) combined with indapamide (0." | 1.31 | Protective effects of delapril combined with indapamide or hydrochlorothiazide in spontaneously hypertensive stroke-prone rats: a comparative dose-response analysis. ( Agnati, LF; Biagini, G; Boschi, S; Torri, C; Vantaggiato, G; Zini, I; Zoli, M, 2000) |
| "Enalapril treatment significantly reduced proteinuria (731 +/- 23 vs." | 1.29 | Effects of antihypertensive drugs on the progress of renal failure in hyperlipidemic Imai rats. ( Baba, N; Sakemi, T, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 15 (28.30) | 18.7374 |
| 1990's | 6 (11.32) | 18.2507 |
| 2000's | 17 (32.08) | 29.6817 |
| 2010's | 15 (28.30) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cunha, MR | 1 |
| Cunha, AR | 1 |
| Marques, BCAA | 1 |
| Mattos, SS | 1 |
| D'El-Rei, J | 1 |
| França, NM | 1 |
| Oigman, W | 1 |
| Neves, MF | 1 |
| Momeni, A | 1 |
| Behradmanesh, MS | 1 |
| Kheiri, S | 1 |
| Karami Horestani, M | 1 |
| Hoshino, T | 1 |
| Ookawara, S | 1 |
| Miyazawa, H | 1 |
| Ito, K | 1 |
| Ueda, Y | 1 |
| Kaku, Y | 1 |
| Hirai, K | 1 |
| Mori, H | 1 |
| Yoshida, I | 1 |
| Tabei, K | 1 |
| Fujisaki, K | 1 |
| Tsuruya, K | 1 |
| Nakano, T | 1 |
| Taniguchi, M | 1 |
| Higashi, H | 1 |
| Katafuchi, R | 1 |
| Kanai, H | 1 |
| Nakayama, M | 1 |
| Hirakata, H | 1 |
| Kitazono, T | 1 |
| Guan, Z | 1 |
| Singletary, ST | 1 |
| Cha, H | 1 |
| Van Beusecum, JP | 1 |
| Cook, AK | 1 |
| Pollock, JS | 1 |
| Pollock, DM | 1 |
| Inscho, EW | 1 |
| Zaitseva, EN | 1 |
| Dubishchev, AV | 1 |
| Yakovlev, DS | 1 |
| Anisimova, VA | 1 |
| Xue, C | 1 |
| Zhou, C | 1 |
| Yang, B | 1 |
| Lv, J | 1 |
| Dai, B | 1 |
| Yu, S | 1 |
| Wang, Y | 1 |
| Zhao, G | 1 |
| Mei, C | 1 |
| Waanders, F | 5 |
| Vaidya, VS | 1 |
| van Goor, H | 1 |
| Leuvenink, H | 1 |
| Damman, K | 1 |
| Hamming, I | 1 |
| Bonventre, JV | 1 |
| Vogt, L | 5 |
| Navis, G | 5 |
| Blanchard, A | 1 |
| Vargas-Poussou, R | 1 |
| Peyrard, S | 1 |
| Mogenet, A | 1 |
| Baudouin, V | 1 |
| Boudailliez, B | 1 |
| Charbit, M | 1 |
| Deschesnes, G | 1 |
| Ezzhair, N | 1 |
| Loirat, C | 1 |
| Macher, MA | 1 |
| Niaudet, P | 1 |
| Azizi, M | 1 |
| Perico, N | 1 |
| Cattaneo, D | 1 |
| Remuzzi, G | 2 |
| Kim, KS | 1 |
| Fan, WH | 1 |
| Kim, YD | 1 |
| Zhu, W | 1 |
| Ngau, YY | 1 |
| Tong, P | 1 |
| Kim, BS | 1 |
| Santos, M | 1 |
| Lin, WH | 1 |
| Buranakitjaroen, P | 1 |
| Massaad, R | 1 |
| Smith, RD | 1 |
| Krikken, JA | 1 |
| Dallinga-Thie, GM | 1 |
| Dikkeschei, LD | 1 |
| Navis, GJ | 1 |
| Dullaart, RP | 1 |
| Abe, M | 2 |
| Okada, K | 2 |
| Maruyama, T | 2 |
| Matsumoto, K | 2 |
| Matsumoto, S | 1 |
| Slagman, MC | 2 |
| Sinkeler, SJ | 1 |
| Hemmelder, MH | 3 |
| Kluin-Nelemans, HC | 1 |
| Laverman, GD | 2 |
| Thornton, SN | 1 |
| Kujal, P | 1 |
| Chábová, VČ | 1 |
| Vernerová, Z | 1 |
| Walkowska, A | 1 |
| Kompanowska-Jezierska, E | 1 |
| Sadowski, J | 1 |
| Vaňourková, Z | 1 |
| Husková, Z | 1 |
| Opočenský, M | 1 |
| Skaroupková, P | 1 |
| Schejbalová, S | 1 |
| Kramer, HJ | 1 |
| Rakušan, D | 1 |
| Malý, J | 1 |
| Netuka, I | 1 |
| Vaněčková, I | 1 |
| Kopkan, L | 1 |
| Cervenka, L | 1 |
| Nguyen, TQ | 1 |
| Goldschmeding, R | 1 |
| Murphy, SR | 1 |
| Dahly-Vernon, AJ | 1 |
| Dunn, KM | 1 |
| Chen, CC | 1 |
| Ledbetter, SR | 1 |
| Williams, JM | 1 |
| Roman, RJ | 1 |
| Villa, L | 1 |
| Boor, P | 1 |
| Konieczny, A | 1 |
| Kunter, U | 1 |
| van Roeyen, CR | 1 |
| Denecke, B | 1 |
| Gan, L | 1 |
| Neusser, MA | 1 |
| Cohen, CD | 1 |
| Eitner, F | 1 |
| Scholl, T | 1 |
| Ostendorf, T | 1 |
| Floege, J | 1 |
| Zhang, J | 1 |
| Xia, ZK | 1 |
| SHUBECK, F | 1 |
| TATUM, HJ | 1 |
| RODARI, T | 1 |
| REGAZZINI, A | 1 |
| TRONCONI, L | 1 |
| Soto, K | 1 |
| Gómez-Garre, D | 1 |
| Largo, R | 1 |
| Gallego-Delgado, J | 1 |
| Tejera, N | 1 |
| Catalán, MP | 1 |
| Ortiz, A | 1 |
| Plaza, JJ | 1 |
| Alonso, C | 1 |
| Egido, J | 1 |
| Lehnert, H | 1 |
| Bramlage, P | 2 |
| Pittrow, D | 1 |
| Kirch, W | 2 |
| Sharma, AM | 1 |
| van Nieuwkoop, C | 1 |
| Ijpelaar, DH | 1 |
| Bolk, JH | 1 |
| Fogari, R | 1 |
| Corradi, L | 1 |
| Zoppi, A | 1 |
| Lazzari, P | 1 |
| Mugellini, A | 1 |
| Preti, P | 1 |
| Rinaldi, A | 1 |
| Reungjui, S | 1 |
| Hu, H | 1 |
| Mu, W | 1 |
| Roncal, CA | 1 |
| Croker, BP | 1 |
| Patel, JM | 1 |
| Nakagawa, T | 1 |
| Srinivas, T | 1 |
| Byer, K | 1 |
| Simoni, J | 1 |
| Wesson, D | 1 |
| Sitprija, V | 1 |
| Johnson, RJ | 1 |
| Boomsma, F | 1 |
| de Zeeuw, D | 2 |
| Tylicki, L | 1 |
| Rutkowski, P | 1 |
| Renke, M | 1 |
| Larczyński, W | 1 |
| Aleksandrowicz, E | 1 |
| Lysiak-Szydlowska, W | 1 |
| Rutkowski, B | 1 |
| Proniewska, W | 2 |
| Vidt, DG | 1 |
| Salti, IS | 1 |
| Hemady, K | 1 |
| Moyer, JH | 1 |
| Sakemi, T | 1 |
| Baba, N | 1 |
| Ono, Y | 1 |
| Ono, H | 1 |
| Frohlich, ED | 1 |
| Buter, H | 1 |
| de Jong, PE | 1 |
| Schwenger, V | 1 |
| Zeier, M | 1 |
| Ritz, E | 1 |
| Fabris, B | 1 |
| Candido, R | 1 |
| Armini, L | 1 |
| Fischetti, F | 1 |
| Calci, M | 1 |
| Bardelli, M | 1 |
| Fazio, M | 1 |
| Campanacci, L | 1 |
| Carretta, R | 1 |
| Boschi, S | 1 |
| Vantaggiato, G | 1 |
| Torri, C | 1 |
| Zini, I | 1 |
| Agnati, LF | 1 |
| Zoli, M | 1 |
| Biagini, G | 1 |
| Voyaki, SM | 1 |
| Staessen, JA | 1 |
| Thijs, L | 1 |
| Wang, JG | 1 |
| Efstratopoulos, AD | 1 |
| Birkenhäger, WH | 1 |
| de Leeuw, PW | 1 |
| Leonetti, G | 1 |
| Nachev, C | 1 |
| Rodicio, JL | 1 |
| Tuomilehto, J | 1 |
| Fagard, R | 1 |
| Ruggenenti, P | 1 |
| Brenner, BM | 2 |
| Bakris, GL | 1 |
| Barnhill, BW | 1 |
| Sadler, R | 1 |
| Anderson, S | 1 |
| Rennke, HG | 1 |
| Riechers, G | 1 |
| Futerova, M | 1 |
| Hanisch, M | 1 |
| Ritter, W | 1 |
| Kühn, K | 1 |
| Groover, ME | 1 |
| Fulghum, JE | 1 |
| Simpson, WG | 1 |
| Precht, K | 1 |
| Klinkmann, H | 1 |
| Haller, J | 1 |
| Gjonnaess, H | 1 |
| Schneider, PJ | 1 |
| Eytel, CS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparison of Efficacy and Safety Between Benidipine and Hydrochlorothiazide in Fosinopril Treated Chronic Kidney Disease Patients With Hypertension: a Randomized Controlled Trial[NCT02646397] | Phase 4 | 508 participants (Anticipated) | Interventional | 2016-02-29 | Not yet recruiting | ||
| Pharmacodynamic Evaluation of the ANTICALCIURIC Effect of Hydrochlorothiazide in Dent's Disease[NCT00638482] | Phase 2/Phase 3 | 10 participants (Actual) | Interventional | 2003-07-31 | Terminated (stopped due to terminated) | ||
| An Open Label Study to Assess the Efficacy of Losartan/HCTZ Combination Therapy in Patients With Essential Hypertension Who Were Inadequately Controlled on Current Antihypertensive Monotherapy[NCT00354991] | Phase 3 | 437 participants (Actual) | Interventional | 2006-06-01 | Completed | ||
| DD-study: Diet or Diuretics for Salt-sensitivity in Chronic Kidney Disease[NCT02875886] | Phase 4 | 28 participants (Actual) | Interventional | 2016-09-30 | Completed | ||
| Uric Acid and Hypertension in African Americans[NCT00241839] | Phase 3 | 150 participants (Actual) | Interventional | 2005-08-31 | Completed | ||
| Effects of Low Sodium Intake on the Anti-proteinuric Efficacy of Olmesartan in Hypertensive Patients With Albuminuria Through Open-label Randomized Trial[NCT01552954] | Phase 4 | 269 participants (Actual) | Interventional | 2012-02-29 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The Diastolic BP was taken at Baseline and after 8-10 weeks of treatment or placebo while on chlorthalidone and potassium chloride. The blood pressure was measured according to Shared Care protocol: 15 minutes of quiet, undisturbed rest with three BP measurements obtained subsequently at 5 minute intervals.~The mean of the second and third reading was the value used for analysis for both the Baseline measurement and the measurement after 8 - 10 weeks of treatment. The dependent variable is baseline value minus ending value.~Measures are in millimeters of mercury (mm hg)" (NCT00241839)
Timeframe: Measured at 8-10 weeks on allopurinol / placebo
| Intervention | mm Hg (Mean) |
|---|---|
| A (Allopurinol) | 3.44 |
| B (Placebo) | -0.83 |
Subjects had 24 hr blood pressure monitoring (ABPM) at baseline and treatment end. The readings were averaged and the changes from baseline to treatment end were compared. (NCT00241839)
Timeframe: Baseline and end of treatment (8-10 weeks on allopurinol / placebo)
| Intervention | mm Hg (Mean) |
|---|---|
| A (Allopurinol) | -5.9 |
| B (Placebo) | 0.90 |
"The systolic BP was taken at Baseline and after 8-10 weeks of treatment on placebo, while on chlorthalidone and potassium chloride. The blood pressure was measured according to Shared Care protocol: 15 minutes of quiet, undisturbed rest with three BP measurements obtained subsequently at 5 minute intervals.~The mean of the second and third reading was the value used for analysis for both the Baseline measurement and the measurement after 8 - 10 weeks of treatment. The dependent variable is baseline value minus ending value.~Measures are in millimeters of mercury (mm hg)" (NCT00241839)
Timeframe: Measured at 8-10 weeks on allopurinol or placebo
| Intervention | mm Hg (Mean) |
|---|---|
| A (Allopurinol) | 0.21 |
| B (Placebo) | -0.95 |
Subjects on allopurinol are expected to lower their uric acid levels relative to placebo. (NCT00241839)
Timeframe: Baseline UA levels compared to end of treatment levels (8-10 weeks on allopurinol / placebo)
| Intervention | mg/dl (Mean) |
|---|---|
| A (Allopurinol) | 2.29 |
| B (Placebo) | 0.14 |
"Change in albuminuria as a 24-hour urine protein excretion by intensive education of low salt diet during taking olmesartan~*In outcome measure data table, the 24-hour urine collection at 16th week was omitted in 3 out of 245 patients (1 for intensive education group and 2 for conventional education group). Values of each study week were mean of all participants on specific study week, but ∆albuminuria (week 8 - week 16) value was mean of ∆ values of 8 weeks-16 weeks in each individuals. Therefore, values of 3 patients were excluded in mean of ∆albuminuria (week 8 - week 16). That's why simple subtraction (week 8 - week 16) of values are not matched with the data." (NCT01552954)
Timeframe: changes from week 8 at week 16 (week 8 - week 16)
| Intervention | mg/day (Mean) | ||
|---|---|---|---|
| 24hr-urine albumin (8th week) | 24hr-urine albumin (16th week);n=124, 118 | Mean of ∆albuminuria (week 8-week 16); n=124, 118 | |
| Conventional Education of Low-salt Diet Group | 483.5 | 487.3 | -0.4 |
| Intensive Education of Low-salt Diet Group | 569.9 | 417.4 | 154.0 |
The change of hemoglobin after prescription of Olmesartan (NCT01552954)
Timeframe: 0 week, 16 weeks
| Intervention | g/dL (Mean) | |||
|---|---|---|---|---|
| Hemoglobin (week 0) | Hemoglobin (week 8) | Hemoglobin (week 16) | Hemoglobin changes from week 0 at week 16 | |
| Conventional Education of Low-salt Diet Group | 13.8 | 13.5 | 13.3 | 0.46 |
| Intensive Education of Low-salt Diet Group | 14.0 | 13.7 | 13.4 | 0.62 |
Change of sodium excretion rate in 24 hour-urine collection by intensive education for low salt diet at week 16 (NCT01552954)
Timeframe: week 8 and week 16
| Intervention | mEq/day (Mean) | ||
|---|---|---|---|
| week 8 | week 16; n=124, 118 | ∆Na excretion (week 8 - week 16);n=124, 118 | |
| Conventional Education of Low-salt Diet Group | 155.5 | 147.1 | 9.0 |
| Intensive Education of Low-salt Diet Group | 157.4 | 122.1 | 35.4 |
Change in Systolic and Diastolic Blood Pressure from Week 8 to Week 16 in the Intensive Education Group compared to the Conventional Education Group (NCT01552954)
Timeframe: week 8 and week 16
| Intervention | mm Hg (Mean) | |||||
|---|---|---|---|---|---|---|
| Systolic BP at week 8 | Systolic BP at week 16 | sBP changes from week 8 at week 16 | Diastolic BP at week 8 | Diastolic BP at week 16 | dBP changes from week 8 at week 16 | |
| Conventional Education of Low-salt Diet Group | 121.8 | 121.2 | 0.6 | 73.4 | 74.8 | -0.7 |
| Intensive Education of Low-salt Diet Group | 122.1 | 120.4 | 1.7 | 73.6 | 73.1 | 0.5 |
2 reviews available for hydrochlorothiazide and Proteinuria
| Article | Year |
|---|---|
[Clinical characteristics and molecular genetics of Dent's disease: an update].
Topics: Animals; Child; Child, Preschool; Chloride Channels; Dent Disease; Diuretics; Humans; Hydrochlorothi | 2012 |
Drug systems approach to hypertension.
Topics: Captopril; Clonidine; Drug Combinations; Drug Therapy, Combination; Guanethidine; Humans; Hydralazin | 1984 |
20 trials available for hydrochlorothiazide and Proteinuria
| Article | Year |
|---|---|
Evaluation of spironolactone plus hydrochlorothiazide in reducing proteinuria in type 2 diabetic nephropathy.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Blood Glucose; Diabetes Me | 2015 |
Impact of combined losartan/hydrochlorothiazide on proteinuria in patients with chronic kidney disease and hypertension.
Topics: Adult; Aged; Creatinine; Diuretics; Drug Combinations; Drug Therapy, Combination; Female; Glomerular | 2014 |
Comparison of efficacy and safety between benidipine and hydrochlorothiazide in fosinopril-treated hypertensive patients with chronic kidney disease: protocol for a randomised controlled trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antihypertensi | 2017 |
Effect of renin-angiotensin-aldosterone system inhibition, dietary sodium restriction, and/or diuretics on urinary kidney injury molecule 1 excretion in nondiabetic proteinuric kidney disease: a post hoc analysis of a randomized controlled trial.
Topics: Acetylglucosaminidase; Adult; Aged; Antihypertensive Agents; Biomarkers; Chronic Disease; Combined M | 2009 |
Effectiveness of open-label losartan/hydrochlorothiazide combination therapy in Asian patients with hypertension not controlled with ACE inhibitor or ARB monotherapy.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Asia | 2009 |
Antiproteinuric therapy decreases LDL-cholesterol as well as HDL-cholesterol in non-diabetic proteinuric patients: relationships with cholesteryl ester transfer protein mass and adiponectin.
Topics: Adiponectin; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Cholesterol Ester Transfer Protei | 2009 |
Antiproteinuric and blood pressure-lowering effects of a fixed-dose combination of losartan and hydrochlorothiazide in hypertensive patients with stage 3 chronic kidney disease.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Chronic Disease; Creatinine; Dose-Response Relationsh | 2009 |
Blood pressure-lowering and antiproteinuric effect of switching from high-dose angiotensin receptor blockers to normal-dose telmisartan and low-dose hydrochlorothiazide in hypertensive patients with chronic kidney disease.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Be | 2010 |
Erythropoietin is reduced by combination of diuretic therapy and RAAS blockade in proteinuric renal patients with preserved renal function.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Cross-Over Studies; Diuretics; Double-Blind Method; | 2010 |
Effects of antiproteinuric intervention on elevated connective tissue growth factor (CTGF/CCN-2) plasma and urine levels in nondiabetic nephropathy.
Topics: Angiotensin II Type 1 Receptor Blockers; Biomarkers; Chronic Disease; Combined Modality Therapy; Con | 2011 |
[IRMA-pRAcs: irbesartan in the treatment of microalbuminuria and proteinuria in patients with type 2 diabetes and hypertension-prospective observational study involving 38,016 patients in the general practice setting].
Topics: Adolescent; Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agen | 2003 |
[Arterial hypertension in obese patients. Rationale for a prospective medical care study in the family doctor's practice].
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; C | 2004 |
Addition of manidipine improves the antiproteinuric effect of candesartan in hypertensive patients with type II diabetes and microalbuminuria.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compound | 2007 |
Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan.
Topics: Adult; Aged; Aldosterone; Antihypertensive Agents; Blood Pressure; Cross-Over Studies; Drug Interact | 2008 |
Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.
Topics: Acetylglucosaminidase; Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2008 |
A controlled multiclinic study to compare the antihypertensive effects of MK-421, hydrochlorothiazide, and MK-421 combined with hydrochlorothiazide in patients with mild to moderate essential hypertension.
Topics: Adult; Aged; Analysis of Variance; Black or African American; Blood Pressure; Clinical Trials as Top | 1984 |
Low-dose captopril for the treatment of mild to moderate hypertension. I. Results of a 14-week trial. Veterans Administration Cooperative Study Group on Antihypertensive Agents.
Topics: Adult; Aged; Captopril; Clinical Trials as Topic; Drug Eruptions; Drug Therapy, Combination; Humans; | 1984 |
Follow-up of renal function in treated and untreated older patients with isolated systolic hypertension. Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.
Topics: Aged; Antihypertensive Agents; Creatinine; Diabetes Complications; Double-Blind Method; Enalapril; E | 2001 |
Treatment of arterial hypertension in diabetic humans: importance of therapeutic selection.
Topics: Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus, Type 2; Dipeptides; Drug Combinations; | 1992 |
Effects of muzolimine and of a combination of hydrochlorothiazide/triamterene in healthy subjects and in nephrotic patients.
Topics: Adolescent; Adult; Aged; Body Weight; Creatinine; Drug Therapy, Combination; Electrolytes; Female; H | 1985 |
31 other studies available for hydrochlorothiazide and Proteinuria
| Article | Year |
|---|---|
Association of urinary sodium/potassium ratio with structural and functional vascular changes in non-diabetic hypertensive patients.
Topics: Adult; Aged; Blood Pressure; Blood Pressure Determination; C-Reactive Protein; Carotid-Femoral Pulse | 2019 |
Renoprotective effects of thiazides combined with loop diuretics in patients with type 2 diabetic kidney disease.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Diabeti | 2015 |
Pentosan polysulfate preserves renal microvascular P2X1 receptor reactivity and autoregulatory behavior in DOCA-salt hypertensive rats.
Topics: Adenosine Triphosphate; Animals; Anti-Inflammatory Agents; Antihypertensive Agents; Arterioles; Bloo | 2016 |
[NEPHROPROTECTIVE PROPERTIES OF 5-HT3 RECEPTOR BLOCKER RU-63 IN EXPERIMENTAL ACUTE RENAL FAILURE UNDER HYPERGRAVITY CONDITIONS].
Topics: Acute Kidney Injury; Animals; Benzimidazoles; Creatinine; Diuretics; gamma-Glutamyltransferase; Glom | 2016 |
Effect of hydrochlorothiazide on urinary calcium excretion in dent disease: an uncontrolled trial.
Topics: Adolescent; Calcium; Child; Diuretics; Humans; Hydrochlorothiazide; Hypercalciuria; Hypophosphatemia | 2008 |
Kidney injury molecule 1: in search of biomarkers of chronic tubulointerstitial damage and disease progression.
Topics: Animals; Antihypertensive Agents; Biomarkers; Chronic Disease; Disease Models, Animal; Disease Progr | 2009 |
RAAS blockade in combination with diuretic therapy increases urine excretion, which in turn increases drinking and thus reduces erythropoietin and proteinuria.
Topics: Chronic Disease; Diuretics; Drinking Behavior; Drug Therapy, Combination; Erythropoietin; Hemodiluti | 2010 |
Similar renoprotection after renin-angiotensin-dependent and -independent antihypertensive therapy in 5/6-nephrectomized Ren-2 transgenic rats: are there blood pressure-independent effects?
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2010 |
Renoprotective effects of anti-TGF-β antibody and antihypertensive therapies in Dahl S rats.
Topics: Acute Kidney Injury; Animals; Antibodies, Anti-Idiotypic; Antihypertensive Agents; Blood Pressure; C | 2012 |
Late angiotensin II receptor blockade in progressive rat mesangioproliferative glomerulonephritis: new insights into mechanisms.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Atenolol; Benzimidazoles; | 2013 |
PROPHYLACTIC USE OF CHLORTHALIDONE IN PREGNANCY.
Topics: Blood Pressure; Chlorthalidone; Eclampsia; Edema; Female; Humans; Hydrochlorothiazide; Infant, Newbo | 1964 |
[Action of hydrochlorothiazide on nephrotic proteinuria].
Topics: Body Fluids; Chlorothiazide; Humans; Hydrochlorothiazide; Nephrotic Syndrome; Proteinuria; Urinalysi | 1961 |
Tight blood pressure control decreases apoptosis during renal damage.
Topics: Animals; Antihypertensive Agents; Apoptosis; Blood Pressure; Cell Division; Drug Therapy, Combinatio | 2004 |
Treating proteinuria in a diabetic patient despite hyperkalaemia due to hyporeninaemic hypoaldosteronism.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Diabetes Mellitus, Type 2; Diabet | 2007 |
Thiazide-induced subtle renal injury not observed in states of equivalent hypokalemia.
Topics: Aldosterone; Animals; Blood Pressure; Body Weight; Diuretics; Hydrochlorothiazide; Hypertension, Ren | 2007 |
[Behavior of protein in the 24-hour urine after administration of certain diuretics].
Topics: Acetazolamide; Adolescent; Adult; Aged; Heart Failure; Humans; Hydrochlorothiazide; Middle Aged; Org | 1967 |
Hypercalciuric rickets: a rare cause of nephrolithiasis.
Topics: Acidosis, Renal Tubular; Adult; Calcium; Cyclic AMP; Glucose; Glycosuria; Humans; Hydrochlorothiazid | 1980 |
Effects of antihypertensive drugs on the progress of renal failure in hyperlipidemic Imai rats.
Topics: Animals; Antihypertensive Agents; Cholesterol; Drug Therapy, Combination; Enalapril; Hydralazine; Hy | 1993 |
Hydrochlorothiazide exacerbates nitric oxide-blockade nephrosclerosis with glomerular hypertension in spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Diuretics; Hemodynamics; Hydrochlorothiazide; Hypertension; Kidney | 1996 |
The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Diet, Sodium-Restricted; Diuretics; | 1998 |
Antihypertensive therapy in renal patients - benefits and difficulties.
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive A | 1999 |
Control of glomerular hyperfiltration and renal hypertrophy by an angiotensin converting enzyme inhibitor prevents the progression of renal damage in hypertensive diabetic rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressure; Diabetic | 1999 |
Protective effects of delapril combined with indapamide or hydrochlorothiazide in spontaneously hypertensive stroke-prone rats: a comparative dose-response analysis.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Body Weight; Diuretics; Dose-Resp | 2000 |
Remission achieved in chronic nephropathy by a multidrug approach targeted at urinary protein excretion.
Topics: Adult; Algorithms; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Diure | 2001 |
Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Enalapril; Glomerular Filtration Rate; Hydralazin | 1986 |
Arterial hypertension--northwest Florida public health survey. II. Diagnosis and treatment.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Blood Urea Nitrogen; Chlorothiazide; Diuretics | 1974 |
[The nephrotic syndrome, clinical features and therapy].
Topics: Adrenocorticotropic Hormone; Adult; Humans; Hydrochlorothiazide; Male; Nephrotic Syndrome; Penicilli | 1965 |
[Therapy of EPH gestosis].
Topics: Chlorthalidone; Diazepam; Diet Therapy; Eclampsia; Edema; Female; Furosemide; Guanethidine; Humans; | 1973 |
Thiazide treatment in pregnancy with special reference to maternal and foetal electrolytes.
Topics: Adolescent; Adult; Blood Chemical Analysis; Chlorides; Diuretics; Edema; Female; Humans; Hydrochloro | 1968 |
The nephrotic syndrome in an elderly woman. An unusual association with an unusual response to therapy.
Topics: Aged; Biopsy; Body Weight; Chronic Disease; Diagnosis, Differential; Edema; Female; Humans; Hydrochl | 1969 |
[Urinary protein content after the administration of some diuretics].
Topics: Acetazolamide; Female; Humans; Hydrochlorothiazide; Male; Organomercury Compounds; Proteinuria | 1965 |